Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of NWRD08 in HPV16/18-positive cervical HSIL
CTR20253520Phase 2Active
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Nov 2025
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NWRD08 in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, sponsored by Newish Technology (Beijing) Co., Ltd.. Started Nov 2025; status: active.
02
Drugs
NWRD08
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on CTR20253520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253520.